|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||420.479 g/mol g·mol−1|
|3D model (JSmol)|
Filorexant (INN, USAN) (code name MK-6096) is an orexin antagonist which is or was under development by Merck for the treatment of insomnia. It is a dual antagonist of the OX1 and OX2 receptors. As of March 2014[update], filorexant has completed phase II clinical trials. It was also investigated as a migraine prophylaxis, but was not found effective, and in major depressive disorder and painful diabetic neuropathy. As of May 2015[update], filorexant is no longer listed on Merck's online development pipeline.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|